Structure Therapeutics’ (NASDAQ:GPCR – Get Rating) quiet period will end on Wednesday, March 15th. Structure Therapeutics had issued 10,740,000 shares in its public offering on February 3rd. The total size of the offering was $161,100,000 based on an initial share price of $15.00. During the company’s quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
Wall Street Analysts Forecast Growth
Several analysts have recently weighed in on GPCR shares. SVB Securities started coverage on Structure Therapeutics in a report on Tuesday, February 28th. They issued an “outperform” rating and a $33.00 target price for the company. SVB Leerink reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, February 28th. Jefferies Financial Group assumed coverage on Structure Therapeutics in a research note on Tuesday, February 28th. They set a “buy” rating and a $34.00 price objective for the company. Guggenheim assumed coverage on Structure Therapeutics in a research note on Tuesday, February 28th. They set a “buy” rating and a $50.00 price objective for the company. Finally, BMO Capital Markets assumed coverage on Structure Therapeutics in a research note on Tuesday, February 28th. They set an “outperform” rating and a $40.00 price objective for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics has an average rating of “Buy” and a consensus price target of $39.25.
Structure Therapeutics Price Performance
Shares of GPCR stock opened at $25.92 on Wednesday. Structure Therapeutics has a 12-month low of $20.80 and a 12-month high of $30.00.
About Structure Therapeutics
Structure Therapeutics Inc is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. Structure Therapeutics Inc is based in SAN FRANCISCO.
See Also
- Get a free copy of the StockNews.com research report on Structure Therapeutics (GPCR)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
